Announced details
Recurrent esophageal squamous cell carcinoma; GPC-1-positive recurrent and refractory solid tumors
The Company receives face-to-face consultation from PMDA concerning the clinical trial plan. The project was selected for an AMED open call program and receives support from AMED. The clinical trial is scheduled to be conducted at Kyoto University Hospital. Capital and personnel relationships are Not disclosed.
PMDA is an incorporated administrative agency, and AMED is a national research and development agency. The planned trial site is the Next-Generation Medicine and iPS Cell Therapy Research Center (Ki-CONNECT), Kyoto University Hospital. Other information on location, representative, capital and year of establishment is Not disclosed.
The impact on consolidated results for the current fiscal year is expected to be immaterial.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | GPC-1 CAR-T therapy |
| Counterparty | Pharmaceuticals and Medical Devices Agency (PMDA), Japan Agency for Medical Research and Development (AMED), Next-Generation Medicine and iPS Cell Therapy Research Center (Ki-CONNECT), Kyoto University Hospital |
| Counterparty overview | PMDA is an incorporated administrative agency, and AMED is a national research and development agency. The planned trial site is the Next-Generation Medicine and iPS Cell Therapy Research Center (Ki-CONNECT), Kyoto University Hospital. Other information on location, representative, capital and year of establishment is Not disclosed. |
| Relationship with the Company | The Company receives face-to-face consultation from PMDA concerning the clinical trial plan. The project was selected for an AMED open call program and receives support from AMED. The clinical trial is scheduled to be conducted at Kyoto University Hospital. Capital and personnel relationships are Not disclosed. |
| Applicable area | Recurrent esophageal squamous cell carcinoma; GPC-1-positive recurrent and refractory solid tumors |
| Impact on Business Performance | The impact on consolidated results for the current fiscal year is expected to be immaterial. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Based on the discussions held during the face-to-face consultation with PMDA.